DPW - /media/Files/S/Shire-IR/annual...آ  2015-02-16آ  DPW Company: SHIRE PLC Submission Type: 10-K

  • View
    0

  • Download
    0

Embed Size (px)

Text of DPW - /media/Files/S/Shire-IR/annual...آ  2015-02-16آ  DPW Company: SHIRE PLC Submission Type:...

  • DPW Company: SHIRE PLC

    Submission Type: 10-K

    Job: 18553_034/DP21071_10K

    Date: 2/23/2011 2:50 PM

  • Submission Data File

    Generated by DPW

    Submission Information Field Name Data Form Type* 10-K Filer CIK* 0000936402 Filer CCC* ******** Filer File Number* Filer is Shell Company* No Filer is Voluntary Filer* No Filer is Well Known Seasoned Issuer* Yes Filer Accelerated Status* Large Accelerated Filer Period of Report* 12-31-10 Return Copy off Confirming Copy off Contact Name Tiaan Schreuder Contact Number 011-44-20-7418-1328 SROS NASD Notify via Website only off Filer is Smaller Reporting Company off

    (End Submission Information)

    Documents Field Name Data Enclosed Document Count 12 Document Name dp21071_10k.htm Document Type* 10-K Document Description FORM 10-K Document Name 1 dp21071_ex1028.htm Document Type* 1 EX-10.28 Document Description 1 EXHIBIT 10.28 Document Name 2 dp21071_ex21.htm Document Type* 2 EX-21 Document Description 2 EXHIBIT 21 Document Name 3 dp21071_ex23-1.htm Document Type* 3 EX-23.1 Document Description 3 EXHIBIT 23.1 Document Name 4 dp21071_ex23-2.htm Document Type* 4 EX-23.2 Document Description 4 EXHIBIT 23.2 Document Name 5 dp21071_ex31-1.htm Document Type* 5 EX-31.1 Document Description 5 EXHIBIT 31.1 Document Name 6 dp21071_ex31-2.htm Document Type* 6 EX-31.2 Document Description 6 EXHIBIT 31.2 Document Name 7 dp21071_ex32-1.htm Document Type* 7 EX-32.1 Document Description 7 EXHIBIT 32.1 Document Name 8 p83b.jpg Document Type* 8 GRAPHIC Document Description 8 Document Name 9 p86.jpg Document Type* 9 GRAPHIC Document Description 9 Document Name 10 p92.jpg Document Type* 10 GRAPHIC Document Description 10 Document Name 11 p83a.jpg Document Type* 11 GRAPHIC Document Description 11

    (End Documents)

    Notifications Field Name Data Email Address edgar@dpw.com Email Address 1 tiaan.schreuder@davispolk.com Email Address 2 bhupinder.grewal@davispolk.com

    (End Notifications)

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 FORM 10-K

    For the fiscal year ended December 31, 2010

    Commission file number 0-29630

    SHIRE PLC (Exact name of registrant as specified in its charter)

    Name : dp21071_10k.htm Type : 10-K Page : 1 Description : FORM 10-K Job : 18553_034/DP21071_10KDate : 2/23/2011 2:50 PM

    [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Jersey (Channel Islands) (State or other jurisdiction of incorporation or organization)

    98-0601486 (I.R.S. Employer Identification No.)

    5 Riverwalk, Citywest Business Campus, Dublin 24, Republic of Ireland

    (Address of principal executive offices and zip code) +353 1 429 7700

    (Registrant’s telephone number, including area code)

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class Name of exchange on which registered

    American Depositary Shares, each representing three Ordinary Shares 5 pence par value per share

    NASDAQ Global Select Market

    Securities registered pursuant to Section 12(g) of the Act:

    None

    (Title of class)

    1

  • Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K. [X] Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

    Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X] Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ] As at June 30, 2010, the last business day of the Registrant’s most recently completed second quarter, the aggregate market value of the ordinary shares, £0.05 par value per share of the Registrant held by non-affiliates was approximately $11,085 million. This was computed using the average bid and asked price at the above date. As at February 11, 2011, the number of outstanding ordinary shares of the Registrant was 562,225,943.

    dp21071_10k.htm 18553_034/DP21071_10K 2/23/2011 2:50 PM 2

    Large accelerated filer [X] Accelerated filer Non-accelerated filer Smaller reporting company

    2

  • THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The following are trademarks either owned or licensed by Shire plc or its subsidiaries, which are the subject of trademark registrations in certain territories, or which are owned by third parties as indicated and referred to in this Form 10-K: ADDERALL XR® (mixed salts of a single entity amphetamine) ADDERALL® (mixed salts of a single entity amphetamine) AGRYLIN® (anagrelide hydrochloride) APRISO® (trademark of Salix Pharmaceuticals, Ltd. (“Salix”)) ASACOL® (trademark of Medeva Pharma Suisse AG (used under license by Warner Chilcott Company, LLC (“Warner Chilcott”))) ATRIPLA® (trademark of Bristol Myers Squibb Company (“BMS”) and Gilead Sciences, Inc. (“Gilead”)) BERINERT P® (trademark of Aventis Behring GmbH) CALCICHEW® range (calcium carbonate with or without vitamin D3) CARBATROL® (carbamazepine extended-release capsules) CEREZYME® (trademark of Genzyme Corporation (“Genzyme”)) CINRYZE® (trademark of Viropharma Biologics, Inc.) CLAVERSAL® (trademark of Merckle Recordati) COLAZAL® (trademark of Salix Pharmaceuticals, Inc) COMBIVIR® (trademark of GlaxoSmithKline (“GSK”)) CONCERTA® (trademark of Alza Corporation (“Alza”)) DAYTRANA® (trademark of Noven Pharmaceutical Inc. (“Noven”)) DIPENTUM® (trademark of UCB Pharma Ltd (“UCB”)) DYNEPO® (trademark of Sanofi-Aventis) ELAPRASE® (idursulfase) EPIVIR® (trademark of GSK) EPIVIR-HBV® (trademark of GSK) EPZICOM®/KIVEXA (EPZICOM) (trademark of GSK) EQUASYM® IR (methylphenidate hydrochloride) EQUASYM® XL (methylphenidate hydrochloride) FIRAZYR® (icatibant) FIVASA™ (trademark of Tillotts Pharma AG) FOSRENOL® (lanthanum carbonate) FABRAZYME® (trademark of Genzyme) FOCALIN XR® (trademark of Novartis Pharmaceuticals Corporation (“Novartis”)) HEPTOVIR® (trademark of GSK) INTUNIV® (guanfacine extended release) JUVISTA® (trademark of Renovo Limited (“Renovo”)) KALBITOR® (trademark of Dyax Corporation) KAPVAY® (trademark of Shionogi Pharma, Inc. (“Shionogi”)) LIALDA® (mesalamine) MEDIKINET® (trademark of Medice Arzneimittel Pütter GmbH & Co. KG (“Medice”)) METAZYM™ (arylsulfatase-A) METADATE CD® (trademark of UCB) MEZAVANT® (mesalazine) MICROTROL® (trademark of Supernus Pharmaceuticals, Inc. (“Supernus”)) MOVICOL® (trademark of Edra AG, S.A.) PENTASA® (trademark of Ferring A/S Corp (“Ferring”))

    dp21071_10k.htm 18553_034/DP21071_10K 2/23/2011 2:50 PM 3

    3

  • RAZADYNE® (trade